Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia
Open Access
- 3 February 2023
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 31 (4) , 986-1001
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R01CA134777, R01CA173852, R01HL140961, R01HL146137)
- National Cancer Institute (1U54CA196519)
- V Foundation for Cancer Research
- Riley Children's Foundation
This publication has 63 references indexed in Scilit:
- Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant miceJournal of Clinical Investigation, 2012
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Dual‐specificity MAP kinase phosphatases (MKPs)The FEBS Journal, 2012
- Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variationNucleic Acids Research, 2012
- Non–lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cellsJournal of Experimental Medicine, 2011
- A MEK Inhibitor Abrogates Myeloproliferative Disease in Kras Mutant MiceScience Translational Medicine, 2011
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNature Protocols, 2008
- ADAMs in cancer cell proliferation and progressionCancer Science, 2007
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005